Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 03.09.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers |
| 03.10.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements |
| 24.11.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements |
| 14.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 28.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 14.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Transfer of Listing. Reference is made to Item 5.02 below. Due to the vacancy resulting from Mr. Woodward’s resignatio |
Stammdaten
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Unternehmen & Branche
| Name | GENELUX Corp |
|---|---|
| Ticker | GNLX |
| CIK | 0001231457 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 94,8 Mio. USD |
| Beta | 0,46 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 8,000 | -32,145,000 | -0.86 | 19,027,000 | 11,544,000 |
| 2025-09-30 | 10-Q | -7,950,000 | -0.21 | 24,987,000 | 18,591,000 | |
| 2025-06-30 | 10-Q | -7,456,000 | -0.20 | 32,247,000 | 23,898,000 | |
| 2025-03-31 | 10-Q | -7,492,000 | -0.21 | 38,985,000 | 29,846,000 | |
| 2024-12-31 | 10-K | 8,000 | -29,869,000 | -0.95 | 34,716,000 | 26,274,000 |
| 2024-09-30 | 10-Q | 8,000 | -6,467,000 | -0.19 | 40,270,000 | 33,091,000 |
| 2024-06-30 | 10-Q | 8,000 | -6,576,000 | -0.22 | 45,179,000 | 37,669,000 |
| 2024-03-31 | 10-Q | 8,000 | -7,850,000 | -0.29 | 24,676,000 | 15,084,000 |
| 2023-12-31 | 10-K | 170,000 | -28,297,000 | -1.16 | 27,893,000 | 19,473,000 |
| 2023-12-31 | 10-Q | -28,297,000 | 27,893,000 | 19,473,000 | ||
| 2023-09-30 | 10-Q | 170,000 | -5,345,000 | -0.20 | 34,072,000 | 24,028,000 |
| 2023-06-30 | 10-Q | 170,000 | -5,821,000 | -0.23 | 31,363,000 | 22,256,000 |
| 2023-03-31 | 10-Q | 170,000 | -10,364,000 | -0.53 | 14,616,000 | 2,691,000 |
| 2022-12-31 | 10-Q | -5,207,000 | 5,531,000 | -35,783,000 | ||
| 2022-12-31 | 10-K | 11,068,000 | -5,207,000 | -0.57 | 5,531,000 | -35,783,000 |
| 2022-09-30 | 10-Q | 11,000,000 | 4,909,000 | 0.49 | -32,331,000 | |
| 2022-06-30 | 10-Q | -2,820,000 | 0.31 | -39,063,000 | ||
| 2022-03-31 | 10-Q | -3,801,000 | -36,540,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-25 | Smalling Ralph | Officer, Head of Regulatory | Open Market Sale | -240 | 2.51 | -602.40 | -5,0% | |
| 2026-03-24 | Cappello Joseph | Officer, Chief Technical Officer | Open Market Sale | -906 | 2.42 | -2,192.52 | -18,2% | |
| 2026-03-24 | Zindrick Thomas | Officer, President and CEO | Open Market Sale | -3,582 | 2.42 | -8,668.44 | -71,9% | |
| 2026-03-24 | Yu Yong | Officer, SVP, Clinical Development | Open Market Sale | -906 | 2.42 | -2,192.52 | -18,2% | |
| 2026-03-24 | Smalling Ralph | Officer, Head of Regulatory | Open Market Sale | -345 | 2.42 | -834.90 | -6,9% | |
| 2026-03-02 | Thomas John | Director | Open Market Sale | -10,000 | 2.90 | -28,957.00 | -240,2% | |
| 2025-12-05 | Smalling Ralph | Officer, Head of Regulatory | Open Market Sale | -165 | 4.69 | -773.85 | -6,4% | |
| 2025-12-01 | Thomas John | Director | Open Market Sale | -10,000 | 5.00 | -50,008.00 | -414,8% | |
| 2025-11-17 | Smalling Ralph | Officer, Head of Regulatory | Open Market Sale | -343 | 5.37 | -1,841.70 | -15,3% | |
| 2025-11-17 | Yu Yong | Officer, SVP, Clinical Development | Open Market Sale | -973 | 5.37 | -5,224.43 | -43,3% | |
| 2025-11-17 | Zindrick Thomas | Officer, President and CEO | Open Market Sale | -4,509 | 5.37 | -24,210.62 | -200,8% | |
| 2025-11-17 | Cappello Joseph | Officer, Chief Technical Officer | Open Market Sale | -973 | 5.37 | -5,224.43 | -43,3% | |
| 2025-09-03 | Smalling Ralph | Officer, Head of Regulatory | Open Market Sale | -580 | 3.36 | -1,948.22 | -16,2% | |
| 2025-08-21 | Cappello Joseph | Officer, Chief Technical Officer | Open Market Sale | -1,463 | 3.36 | -4,911.88 | -40,7% | |
| 2025-08-21 | Smalling Ralph | Officer, Head of Regulatory | Open Market Sale | -1,244 | 3.36 | -4,176.61 | -34,6% | |
| 2025-08-21 | Cappello Joseph | Officer, Chief Technical Officer | Open Market Sale | -1,270 | 3.33 | -4,224.91 | -35,0% | |
| 2025-08-21 | Yu Yong | Officer, SVP, Clinical Development | Open Market Sale | -3,219 | 3.36 | -10,807.47 | -89,7% | |
| 2025-08-21 | Zindrick Thomas | Officer, President and CEO | Open Market Sale | -12,673 | 3.33 | -42,159.27 | -349,7% | |
| 2025-05-12 | Smalling Ralph | Officer, Head of Regulatory | Open Market Sale | -1,259 | 2.92 | -3,676.28 | -30,5% | |
| 2025-05-12 | Ryder Sean | Officer, General Counsel | Open Market Sale | -4,475 | 2.92 | -13,067.00 | -108,4% | |
| 2025-05-12 | Zindrick Thomas | Director, Officer, President and CEO | Open Market Sale | -10,764 | 2.92 | -31,430.88 | -260,7% | |
| 2025-05-12 | Yu Yong | Officer, VP, Clinical Trial Operations | Open Market Sale | -5,579 | 2.92 | -16,290.68 | -135,1% | |
| 2025-05-12 | Cappello Joseph | Officer, VP, Pharmaceutical Development | Open Market Sale | -4,737 | 2.92 | -13,832.04 | -114,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.